排序方式: 共有3条查询结果,搜索用时 0 毫秒
1
1.
Alexey Rivkin Sean P. Ahearn Stephanie M. Chichetti Christopher L. Hamblett Yudith Garcia Michelle Martinez Jed L. Hubbs Michael H. Reutershan Matthew H. Daniels Phieng Siliphaivanh Karin M. Otte Chaomin Li Andrew Rosenau Laura M. Surdi Joon Jung Bethany L. Hughes Jamie L. Crispino George N. Nikov Richard E. Middleton Christopher M. Moxham Mark S. Shearman 《Bioorganic & medicinal chemistry letters》2010,20(7):2279-2282
The development of a novel series of purines as γ-secretase modulators for potential use in the treatment of Alzheimer’s disease is disclosed herein. Optimization of a previously disclosed pyrimidine series afforded a series of potent purine-based γ-secretase modulators with 300- to 2000-fold in vitro selectivity over inhibition of Notch cleavage and that selectively reduces Αβ42 in an APP-YAC transgenic mouse model. 相似文献
2.
Wilson KJ Witter DJ Grimm JB Siliphaivanh P Otte KM Kral AM Fleming JC Harsch A Hamill JE Cruz JC Chenard M Szewczak AA Middleton RE Hughes BL Dahlberg WK Secrist JP Miller TA 《Bioorganic & medicinal chemistry letters》2008,18(6):1859-1863
An HTS screening campaign identified a series of low molecular weight phenols that showed excellent selectivity (>100-fold) for HDAC1/HDAC2 over other Class I and Class II HDACs. Evolution and optimization of this HTS hit series provided HDAC1-selective (SHI-1) compounds with excellent anti-proliferative activity and improved physical properties. Dose-dependent efficacy in a mouse HCT116 xenograft model was demonstrated with a phenylglycine SHI-1 analog. 相似文献
3.
Siliphaivanh P Harrington P Witter DJ Otte K Tempest P Kattar S Kral AM Fleming JC Deshmukh SV Harsch A Secrist PJ Miller TA 《Bioorganic & medicinal chemistry letters》2007,17(16):4619-4624
Histone deacetylase (HDAC) inhibitors that target Class I and Class II HDACs are of synthetic and therapeutic interest and ongoing clinical studies indicate that they show great promise for the treatment of cancer. Moreover, Zolinza (vorinostat) was recently approved by the FDA for the treatment of the cutaneous manifestations of cutaneous T-cell lymphoma [Nat. Rev. Drug Disc. 2007, 6, 21]. As part of a broader effort to more fully explore the structure-activity relationships (SAR) of HDAC inhibitors, we sought to identify novel HDAC inhibitor structures through iterative design by utilizing low affinity ligands as synthetic starting points for SAR development. Novel and potent HDAC inhibitors have been identified using this approach and herein we report the optimization of the recognition elements of a novel series of malonyl-derived HDAC inhibitors. 相似文献
1